Uses of &agr;-conotoxin peptides
    5.
    发明授权
    Uses of &agr;-conotoxin peptides 有权
    α-芋螺毒素肽的使用

    公开(公告)号:US06265541B1

    公开(公告)日:2001-07-24

    申请号:US09219446

    申请日:1998-12-23

    IPC分类号: C07K1400

    摘要: The present invention relates to the use of &agr;-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Cys (SEQ ID NO: 1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid and Xaa6 represents a peptide of 3-7 amino acids. Disulfide linkages exist between the first and third cysteines and the second and fourth cysteines. Pro may be replaced with hydroxy-Pro. The C-terminus may contain a hydroxyl or an amide group, preferably an amide group.

    摘要翻译: 本发明涉及具有用于治疗在神经元烟碱乙酰胆碱受体调节的病症的通式的α-芋螺毒素肽的用途。 这些病症包括但不限于心血管疾病,胃动力障碍,尿失禁,尼古丁成瘾,情绪障碍(例如双相情感障碍,单极抑郁,精神抑郁和季节性有效障碍)和小细胞肺癌,以及 小细胞肺癌的定位。 在该式中,Xaa1是des-Xaa1,Tyr,单碘-Tyr或二碘-Tyr,Xaa2是任何氨基酸,Xaa3是任何氨基酸,Xaa4是任何氨基酸,Xaa5是任何氨基酸,Xaa6表示 3-7个氨基酸的肽。 第一和第三半胱氨酸与第二和第四半胱氨酸之间存在二硫键。 Pro可以用羟基替代。 C末端可以含有羟基或酰胺基,优选酰胺基。

    Use of .alpha.-conotoxin MII to treat disorders resulting from
nicotine-stimulated dopamine release
    9.
    发明授权
    Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release 失效
    使用α-毒素MII来治疗由尼古丁刺激的多巴胺释放引起的疾病

    公开(公告)号:US5929034A

    公开(公告)日:1999-07-27

    申请号:US45926

    申请日:1998-03-23

    IPC分类号: A61K38/17 A61K38/00

    CPC分类号: A61K38/1767 Y10S514/813

    摘要: Neuronal nicotinic acetylcholine receptors (nAChRs) are believed to mediate nicotine addiction. In addition, stimulation of nAChRs modulates release of neurotransmitters including dopamine, norepinephrine and serotonin. Thus, pharmacological manipulation of nicotinic receptors has implications for a wide variety of disorders including psychotic, mood, movement and cognitive. For most nAChRs, there are no subtype selective ligands. However, .alpha.-conotoxin MII, a small peptide from the carnivorous marine snail Conus magus, was recently isolated. This peptide has been shown to be a specific antagonist for .alpha.3.beta.2 nicotinic receptors. The peptide potently blocks part, but not all, of nicotine-stimulated dopamine release from rat brain striatal synaptosomes. In contrast it has no effect on potassium stimulated dopamine release. Other .alpha.-conotoxins specifically target distinct neuronal nAChR subtypes. .alpha.-Conotoxins thus represent new lead compounds for CNS disorders.

    摘要翻译: 神经元烟碱乙酰胆碱受体(nAChRs)被认为是介导尼古丁成瘾。 此外,nAChRs的刺激调节神经递质的释放,包括多巴胺,去甲肾上腺素和5-羟色胺。 因此,烟碱受体的药理学操作对各种各样的疾病,包括精神病,情绪,运动和认知有影响。 对于大多数nAChR,没有亚型选择性配体。 然而,α-毒素MII,一种来自肉食海洋蜗牛Conus magus的小肽,最近被隔离。 已经显示该肽是α3β2烟碱受体的特异性拮抗剂。 该肽有力地阻止了大鼠脑纹状体突触体中尼古丁刺激的多巴胺释放的部分,但并非全部。 相反,它对钾刺激的多巴胺释放没有影响。 其他α-酮毒素特异性靶向不同的神经元nAChR亚型。 因此,α-核酸毒素代表CNS疾病的新型铅化合物。